Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration
Faricimab mildly decreased CST and reduced fluid in some nARMD eyes refractory to traditional anti-VEGF agents but had minimal effect on BCVA.
Authors
- Kirk Hou (ORCID: https://orcid.org/0000-0003-1986-3327)
- Yaqoob Qaseem
- Moritz Pettenkofer (ORCID: https://orcid.org/0000-0003-4810-1225)
Institutions
- University of California, Los Angeles (US)
- Doheny Eye Institute (US)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/opth.s483563
- Citations
- 6
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.23